BiomX (NYSEMKT:PHGE) Stock Price Up 22.3% – Should You Buy?

BiomX Inc. (NYSEMKT:PHGE)’s share price rose 22.3% on Monday . The stock traded as high as $0.78 and last traded at $0.90. Approximately 53,300 shares changed hands during trading, a decline of 22% from the average daily volume of 68,601 shares. The stock had previously closed at $0.74.

BiomX Price Performance

The company has a 50 day moving average price of $0.74 and a 200 day moving average price of $0.91. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $16.81 million, a price-to-earnings ratio of -1.25 and a beta of 1.27.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Ikarian Capital LLC acquired a new position in BiomX in the third quarter valued at approximately $911,000. JPMorgan Chase & Co. bought a new stake in shares of BiomX during the fourth quarter valued at about $314,000. Allostery Investments LP purchased a new stake in BiomX during the fourth quarter valued at about $470,000. Finally, Alyeska Investment Group L.P. bought a new position in shares of BiomX in the fourth quarter worth approximately $632,000. Institutional investors own 40.57% of the company’s stock.

BiomX Company Profile

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.